53484-19-8

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Ethyl 1-methyl-1H-benzimidazole-5-carboxylate is utilized as a potential therapeutic agent for various diseases due to its anti-microbial, anti-cancer, and anti-inflammatory properties. Its ability to inhibit key enzymes involved in cellular processes makes it a valuable compound in the search for new treatments.
Used in Organic Synthesis:
In addition to its pharmaceutical applications, ethyl 1-methyl-1H-benzimidazole-5-carboxylate has been investigated for its potential use in organic synthesis. It serves as a building block in the preparation of other biologically active compounds, contributing to the development of novel pharmaceuticals and chemical products.
Used in the Preparation of Biologically Active Compounds:
Ethyl 1-methyl-1H-benzimidazole-5-carboxylate is also employed as a key component in the synthesis of other biologically active compounds. Its unique structure and properties allow it to be a versatile building block, enhancing the development of new drugs and therapeutic agents.

Upstream product

• 71254-71-2 ethyl 4-(methylamino)-3-nitrobenzoate 
• 367-80-6 ethyl 4-fluoro-3-nitrobenzoate 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 64-18-6 formic acid 
• 66315-23-9 ethyl 3-amino-4-(methylamino)benzoate 

Downstream Products

• 115576-91-5 (1-methyl-1H-benzimidazol-5-yl)methanol 
• 916587-20-7 C₁₇H₁₉N₃ 
• 53484-17-6 1-methyl-1H-benzo[d]imidazole-5-carboxylic acid 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

C5A RECEPTOR ANTAGONISTS

The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, Rl, R2, R3, R4, R5, R6, R7, R8, R9, Rl0, RI l, R12, R13, R14, R15, R16, Rl7, R18, Rl9, R20, R21 and R22 are individually and independently selected from the group comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted cyclic amino, carbamoyl (-CONH2), substituted carbamoyl, carboxyl, carbamate, alkoxycarbonyl, substituted alkoxycarbonyl, acylamino, substituted acylamino, sulfamoyl (-SO2NH2), substituted sulfamoyl, haloalkyl, haloalkyloxy, -C(O)H, trialkylsilyl and azido.